Area of research
Genetics · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Chromatin Remodeling and Cancer, and Epigenetics and DNA Methylation.
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor–ligand interactions
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification
Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant
Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Distinct relapse pattern across molecular ependymoma types
Report of the sixth meeting of the European Consortium ‘Care for CMMRD’ (C4CMMRD), Paris, France, November 16th 2022
EPEN-01. DISTINCT RELAPSE PATTERN ACROSS MOLECULAR EPENDYMOMA TYPES
DNA methylation‐array interlaboratory comparison trial demonstrates highly reproducible paediatric CNS tumour classification across 13 international centres
EPEN-12. EZHIP IMPACTS CELLULAR DIFFERENTIATION IN POSTERIOR FOSSA GROUP A EPENDYMOMA
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions
Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study
Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics
The Site of Origin of Medulloblastoma: Surgical Observations Correlated to Molecular Groups
Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
DDDR-17. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions